W. William

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

I. Wistuba, J. Lee, J. Erasmus, 2014, The oncologist.

Prognostic biomarkers in patients with human immunodeficiency virus‐positive disease with head and neck squamous cell carcinoma

Amy Y. Chen, G. Sica, J. Lee, 2017, Head & neck.

Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study

J. Lee, D. Gomez, S. Swisher, 2016, The Lancet. Oncology.

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study.

R. Knoblauch, R. Gentzler, M. Mackean, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.